Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

8.3%

1 terminated/withdrawn out of 12 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 10 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1

1(50.0%)

N/A

1(50.0%)

2Total

Early Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT03311152Not ApplicableCompleted

Circulating Cell-free DNA-based Epigenetic Biomarker MSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis

Role: collaborator

NCT03218423Unknown

Longitudinal Performance of Epi proColon

Role: lead

NCT04027790Completed

Plasma-based Colorectal Cancer Screening Research & Development

Role: lead

NCT03804593Completed

HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)

Role: lead

NCT02198092Completed

Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes

Role: collaborator

NCT01653002Completed

Methylation Level of SHOX2 in Endobronchial Ultrasound With Real-time Guided Transbronchial Needle Aspiration for Lung Cancer Staging

Role: collaborator

NCT01580540Completed

Head to Head Study Epi proColon and FIT

Role: lead

NCT02251782Completed

Adherence to Minimally Invasive Testing

Role: lead

NCT01329718Early Phase 1Completed

Specimens for Septin 9 Performance

Role: lead

NCT01574677Withdrawn

Assessment of Septin9 Biomarker for Detection of Colorectal Cancer in Patients With Positive Fecal Immunochemical Test

Role: lead

NCT00855348Completed

PRESEPT Study: Evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening

Role: lead

NCT00696345Completed

Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay

Role: lead

All 12 trials loaded